Our Scientific Approach
At IpiNovyx Bio, our research is driven by a commitment to precision and innovation.
We are pioneering the development of next-generation more potent and selective proteasome inhibitors to treat cancer, autoimmune and inflammatory diseases. Our goal is to create proteasome targeting therapies that providing patients with safer, more effective treatment options.
The Power of
Proteasome Modulation
Our proprietary technology platform is built on developing more potent, selective, and safe small molecule inhibitors of the proteasome, a key biological vulnerability for cancer and immune cells. By discovering and developing inhibitors that selectively target distinct subunit components of the proteasome, we aim to develop therapies that are more selective, potent and effective in a breadth of indications across cancer and autoimmunity.
How It Works
The proteasome complex plays a key biologic role in cells to degrade intracellular proteins and prevent their accumulation inside cells. In cancer cells which often produce excessive and aberrant proteins, proteasome function is a key pathway for cell survival. The immunoproteasome is a specific type of proteasome that is active in immune cells and is also involved in the regulation of the immune system. In autoimmune and inflammatory diseases, its dysregulation can exacerbate disease progression. We are developing a pipeline of next generation potent, safer, and reversible proteasome inhibitors designed to selectively target and modulate proteasome activity in cancer and immune cells.
Innovative R&D and Strategic Collaborations
Our research and development efforts are powered by strong collaborations with leading academic institutions, including Weill Cornell Medicine and the Hospital for Special Surgery (HSS). Supported by the Daedalus Fund for Innovation and the Tri-Institutional Therapeutics Discovery Institute, our work is guided by the latest scientific advancements. Additionally, our technology is in-licensed through an agreement with Cornell University’s Center for Technology Licensing (CTL), further strengthening our innovation ecosystem.
Our Pipeline
We are advancing a portfolio of highly selective and reversible proteasome inhibitors through preclinical development. These innovative drug candidates are designed to address significant unmet medical needs in cancer, autoimmune and inflammatory diseases. As we progress toward clinical trials, anticipated by mid-2026 for our first program, our focus remains on delivering transformative and safe treatments to improve patients' lives.